Latanoprost Aurovitas

Latanoprost, the active ingredient in Latanoprost Aurovitas, is a prostaglandin analog presented as a topical ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the treatment of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Latanoprost is a prostaglandin analog that reduces intra‑ocular pressure by enhancing aqueous humor outflow, and it is employed in the management of several glaucoma‑related conditions. - Open-angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage and visual field loss. - Ocular hypertension: reduces elevated eye pressure to lower the risk of developing glaucoma. - Secondary glaucoma (e.g., steroid‑induced): helps control pressure when it is raised by other ocular conditions.

Latanoprost may cause ocular and systemic adverse reactions; the most frequently reported events involve the eye.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual brownish pigmentation. - Eye irritation: stinging or burning sensation. - Blurred vision: transient visual disturbances. - Periorbital skin darkening: mild hyperpigmentation around the eye.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Sudden loss of vision: rapid visual acuity decline. - Corneal edema: swelling of the cornea. - Persistent ocular pain: may indicate underlying complication.

Before initiating Latanoprost therapy, clinicians should consider several precautionary measures to ensure patient safety. - Monitor intra‑ocular pressure: regular measurements to assess efficacy. - Assess for ocular infection: avoid use if active eye infection is present. - Avoid in patients with known hypersensitivity: discontinue if allergic signs appear. - Caution in corneal endothelial dysfunction: may exacerbate corneal edema. - Pregnancy and breastfeeding: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost’s IOP‑lowering effect. - Combination with other prostaglandin analogs: increases risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure reduction may cause hypotony. - Topical corticosteroids: may counteract Latanoprost’s pressure‑lowering action. - Systemic carbonic anhydrase inhibitors: potential additive IOP‑lowering effect requiring monitoring.